Page 4 - Rafaelg Amado News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

SHANGHAI, China and CAMBRIDGE, Mass., July 14, 2023 Zai Lab Limited today announced that the first patient has been treated in the mainland China portion of the global registrational, Phase 3.

United statesHong kongUnited kingdomGastroenterol hepatolRui hua xuChristine chiouAlina zhangShaun maccoun xiaoyu chenRafaelg amadoDrug administrationZai lab forwardZai labZai lab limitedHead of global oncology researchChina centerExchange commission

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China s NMPA

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China s NMPA
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomHong kongUnited statesChristine chiouXiaoyu chenAlina zhangRafaelg amadoShaun maccounChangfa xiaZai lab forwardZai lab announcesNational medical products administrationPoint therapeutics incZai labHead of global oncology researchBristol myers squibb

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by

SHANGHAI, China and CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has

Hong kongUnited statesUnited kingdomAlina zhangRafaelg amadoChristine chiouShaun maccounChangfa xiaXiaoyu chenNational medical products administrationBristol myers squibbDrug administrationHead of global oncology researchZai lab limitedPoint therapeutics incExchange commission

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China s NMPA

SHANGHAI, China and CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for repotrec.

United statesHong kongUnited kingdomChristine chiouXiaoyu chenAlina zhangRafaelg amadoChangfa xiaShaun maccounDrug administrationExchange commissionPoint therapeutics incZai lab limitedBristol myers squibbHead of global oncology researchZai lab

Repotrectinib NDA Under NMPA Review for Locally Advanced or Metastatic ROS1+ NSCLC

Repotrectinib NDA Under NMPA Review for Locally Advanced or Metastatic ROS1+ NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Rafaelg amadoNational medical products administrationGlobal oncology researchZai labBristol myers squibbDrug administrationPrescription drug user fee actPoint therapeutics